As one of the six core technology platforms of TreatGut Pharmaceutical Group, the Microbiome-Based Drug Screening and Development Platform  combines artificial intelligence (AI) with  gut microbiota technologies (e.g.,  strain drug screening, strain activity assessment, and dosage form development) to explore the characteristics and functional genes of different  gut microbiota strains,  enabling high-quality data analysis,mining, and interpretation. This greatly improves the efficiency and success rate of drug development, thereby translating microbiome-based pharmaceuticals from  lab-stage research into industrial-scale production.